Page 47 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine CCRT plus nimotuzumab for cervical cancer

and nimotuzumab. In addition, seven patients received effective in the treatment of LACSCC, which may bring
pelvic extended-field RT. All patients well tolerated the great benefits to patients with advanced-stage cancers
treatment. No Grade 4 or higher toxicities were observed. and high-risk factors. However, further investigation was
Hematologic toxicities were the main acute adverse needed due to the short follow-up time and limited sample
reaction. The incidence rates of Grade 3 leukopenia, size. Meanwhile, one patient showed negative EGFR
anemia, and thrombocytopenia were 50.0%, 8.8%, and expression but still had CR, indicating that we did not find
20.6%, respectively. Grade 3 nausea and vomiting were a relationship between EGFR expression and efficacy in
8.8%. No other toxicities of Grade 3 or higher were the study. Thus, further research is needed to explore the
observed. The incidence of G3–4 of late rectal and bladder efficacy.
reactions was only 5.8%. Compared to the previous study,
there was no significant increase in toxicities in this study. Acknowledgments
According to the American surveillance epidemiology and The authors would like to thank everyone in the department,
end results database, the 5-year survival rate for cervical cancer who helped to provide treatment in these patients.
is 66.2%. The LC rate and survival rate of Stage IB2, IIA, IIB,
IIIA, IIIB, and IVA cervical cancer were 60–80% and 60–70%, Funding
80–85% and 75%, 60–80% and 60–65%, 60% and 25–50%, This work was supported by the special fund of the National
[31]
50–60% and 25–50%, and 30% and <10%, respectively . In Clinical Key Specialty Construction Program, P. R. China
the study by Hasselle et al., the median follow-up time was (2021).
26.6 months, and the 3-year DFS and OS rates for IIB–IVA
[25]
cervical cancer were 51.4% and 61.4%, respectively . In Conflict of interest
a retrospective analysis of 1433 cases of IB–IVA cervical No potential conflicts of interest relevant to this article
cancer patients who received IMRT combined with 2D were reported.
HDR brachytherapy and concurrent cisplatin chemotherapy,
the 3-year OS, DFS, and LC were 83.0%, 75.0%, and 87.4%, Author contributions
respectively . The 3-year DFS rates for IB1, IB2, IIA, IIB,
[32]
IIIA, and IVA stages were 90.2%, 87.6%, 84.0%, 76.7%, Conceptualization: Junjie Wang
61.6%, 59.8%, and 25.9%, respectively. The 3-year OS, DFS, Formal analysis: Ang Qu
and LC rates among stage IVA patients were 50.0%, 25.9%, Investigation: Ang Qu, Ping Jiang, Xu Li, Haitao Sun
and 51.7%, respectively. Pötter et al. used MRI-guided Resources: Panfeng Wang, Muyi Zhang, Xiuwen Deng,
brachytherapy combined with CRT to treat 156 patients with Weijuan Jiang
locally advanced (IB–IVA stages) cervical cancer . In their Writing – original draft: Ang Qu, Ping Jiang, Junjie Wang
[33]
study, the median follow-up was 42 months, and the 3-year Writing – review and editing: Panfeng Wang, Muyi Zhang,
LC and OS rates were 95% and 68%, respectively. The 3-year Xiuwen Deng, Weijuan Jiang, Weishu Hua
LC and OS rates for patients whose cervix tumor diameters Ethics approval and consent to participate
were larger than 5 cm were 92% and 65%, respectively. The
3-year LC and OS rates for Stages IB, IIB, and IIIB were 100% The retrospective study was approved by the ethics
and 74%, 96% and 78%, and 86% and 45%, respectively. One committee of Peking University Third Hospital (Approval
study reported that for patients with para-aortic lymph node ID: M2021278).
metastasis cervical cancer who received pelvic extended-field
RT and concurrent chemotherapy, the 5-year OS and PFS Consent for publication
rates were 40%–62.6% and 32%–43.9%, respectively [34,35] . In Not applicable.
this study, for patients with tumor diameters of >5 cm, para-
aortic lymph node metastasis, and Stage IVA, the 3-year OS, Availability of data
DFS, and LC rates significantly increased. However, due to All data generated or analyzed during this study are
the small sample size and short follow-up time, there was no included in this article.
significant difference in survival analysis between the groups.
Thus, CRT combined with nimotuzumab might improve References
efficacy in the treatment of LACSCC.
1. Siegel RL, Miller KD, Jemal A, 2018, Cancer statistics, 2018.
5. Conclusion CA Cancer J Clin, 68: 7–30.

The present study reported that nimotuzumab combined https://doi.org/10.3322/caac.21442
with IMRT and concurrent chemotherapy was safe and 2. Jemal A, Bray F, Center MM, et al., 2011, Global cancer

Volume 1 Issue 1 (2023) 6 https://doi.org/10.36922/arnm.0408